Cathie Wood's Latest Buys: The Trade Desk, Pinterest, and Exact Sciences

Cathie Wood's Ark Invest added to existing positions in The Trade Desk, Pinterest, and Exact Sciences, taking advantage of their recent declines. Wood bought more of these stocks despite their poor performance, seeing them as undervalued and a good opportunity for growth. The Trade Desk's 39% plunge was the largest single-day slide in its nearly nine-year history, but Wood sees it as an overreaction due to slowing business growth.

Cathie Wood, the renowned growth investor and CEO of Ark Invest, has recently added to her positions in The Trade Desk (NASDAQ: TTD), Pinterest (NYSE: PINS), and Exact Sciences (NASDAQ: EXAS), despite their recent declines. This move indicates Wood's belief in the long-term potential of these stocks, which she views as undervalued and ripe for growth.

The Trade Desk experienced a dramatic 39% plunge on Friday, marking the largest single-day slide in its nearly nine-year history as a public company [1]. Despite this significant drop, Wood appears to view the decline as an overreaction to slowing business growth. The company reported a 19% increase in revenue for the second quarter, which was slightly below analysts' expectations. However, the deceleration of business growth heading into the second half of the year has led to investor concerns, resulting in a sharp sell-off.

Pinterest shares tumbled 10% on Friday after the company posted mixed financial results. Revenue rose 17% to $998 million, exceeding market expectations. However, adjusted earnings grew by a mere 33%, falling short of analyst estimates. Despite the setback, Pinterest's global monthly active users have risen by 11% over the past year, indicating continued growth in user engagement and monetization potential [1].

Exact Sciences saw its shares slide 13% since posting a poorly received financial update on Wednesday afternoon. The provider of colorectal cancer screening solutions beat expectations on both ends of the income statement but faced investor concerns over its recent acquisitions and licensing agreements. The company announced a $75 million upfront payment, with the potential for up to $700 million more over time, to secure exclusive U.S. licensing rights to rival Freenome's colorectal cancer screening tests [1].

Wood's strategy of adding to positions in these companies during their recent declines underscores her confidence in their long-term prospects. While the current market conditions may present challenges, Ark Invest's approach suggests a belief in the resilience and growth potential of these stocks.

References:
[1] https://www.mitrade.com/insights/news/live-news/article-8-1029629-20250811
[2] https://www.cnbc.com/2025/08/08/stocks-making-the-biggest-moves-midday-gild-mnst-ttd-mp-sg.html